ICICI Securities Issues “Buy” Recommendation for Tatva Chintan Pharma Chem

In a recent announcement, ICICI Securities has expressed a bullish sentiment on Tatva Chintan Pharma Chem, suggesting investors “buy” the stock with a target price of Rs 2000. As of now, Tatva Chintan Pharma Chem is trading at Rs 1579.15 in the market.

Tatva Chintan Pharma Chem Ltd., a company established in 1996, falls under the Small Cap category and boasts a market capitalization of Rs 3684.25 Crore. It primarily operates within the Chemicals sector.


Key Products and Revenue Segments for Tatva Chintan Pharma Chem Ltd. encompass Speciality Chemicals, Scrap, and Export Incentives, as disclosed in their financial report for the fiscal year ending on 31st March 2022.

Analyzing the company’s financials, for the quarter concluding on 30th June 2023, Tatva Chintan Pharma Chem reported a Consolidated Total Income of Rs 115.38 Crore. This represents a decline of -7.96% compared to the previous quarter’s Total Income of Rs 125.36 Crore. However, it is noteworthy that the company’s performance displayed an impressive year-on-year growth of 27.87%, with the Total Income for the same quarter in the previous year recorded at Rs 90.23 Crore. Furthermore, the latest quarter’s financials reveal a net profit after tax of Rs 9.50 Crore.

ICICI Securities’ “buy” recommendation for Tatva Chintan Pharma Chem is indicative of their positive outlook on the company’s future prospects, with a target price set at Rs 2000. Investors may be considering this recommendation as they evaluate their investment decisions.

Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.​​
We will be happy to hear your thoughts

      Leave a reply

      Share Price India News